A study assessing the impact of anti-interleukin-5 therapy (mepolizumab) on objectively measured cough showed significant reductions in cough frequency after 6 months of therapy [24], supporting the concept that targeting eosinophilic inflammation in severe asthma has an impact on cough. The gene discussed is IL5; the disease is asthma.